ERPY - ERPY STOCK NEWS

Voting Rights Update: As of March 31, 2022, Erytech Pharma reports a total of 31,018,553 shares in its share capital. The gross voting rights are noted at 32,518,547, while net voting rights stand at 32,516,047. This data, in compliance with Article 223-16 of French financial regulations, is crucial for stakeholders monitoring the company's governance and shareholder participation. The report aligns with their listing on Euronext Paris and Nasdaq, ensuring transparency for investors.

ERYTECH will present its innovative vesiculation technology at the 24th Meeting of the European Red Cell Society from April 7 to 11, 2022, in Gazzada Schianno, Italy. The oral presentation, scheduled for April 9 at 11:30 AM, will focus on the feasibility of producing cargo-loaded extracellular vesicles from red blood cells using the ERYCAPS® process, highlighting their potential as a drug delivery system. The company aims to showcase the ERYCEV^TM technology's in vitro biological activity, with implications for future immune modulation therapies.

ERYTECH Pharma (Nasdaq: ERYP) announced their participation in upcoming investor conferences in April 2022, inviting investors for one-on-one meetings.

The Investor Access Event will be held on April 4-5 in Paris, featuring CFO Eric Soyer. Additionally, ERYTECH will attend the Kempen 14th Life Sciences Conference on April 21 in Amsterdam, with CEO Gil Beyen and CFO Eric Soyer as participants.

ERYTECH specializes in red blood cell-based therapeutics, focusing on treating severe cancers with their lead product, eryaspase.

ERYTECH Pharma reported progress in seeking FDA approval for its lead product GRASPA® for patients with hypersensitivity to pegylated asparaginase. Their Biologics License Application (BLA) is nearly ready for submission pending FDA review. The company also disclosed results from its Phase 3 trial for second-line pancreatic cancer, which did not meet its primary endpoint, although some subgroup results were promising. As of December 31, 2021, ERYTECH had cash reserves of €33.7 million, down from €44.4 million in 2020. The company plans to submit BLA in Q2 2022 and anticipates further data in 2022.

Erytech Pharma has disclosed its total share capital and voting rights as of January 31, 2022. The company reports a total of 31,018,553 shares, corresponding to 32,518,339 gross voting rights and 32,515,839 net voting rights. This data reflects the company’s compliance with Article 223-16 of the General Regulation of the French Autorité des Marchés Financiers. The reporting period is crucial for investors monitoring share structure changes and potential voting power shifts.

ERYTECH Pharma has announced the allowance of a US patent application for arginine deiminase (ADI) encapsulated in red blood cells, specifically targeting arginase-1 deficiency (A1D), a rare metabolic disease. This patent expands the scope to include treatments for arginine-dependent cancers, septic shock, and other conditions. ERYTECH's approach aims at improving enzyme replacement therapies by offering better tolerance and longer action. With a patent portfolio of around 310 issued patents and 45 pending applications, the company enhances its clinical application potential beyond oncology.

Monthly Voting Rights Report: As of January 31, 2022, the total number of shares for Erytech Pharma is 31,018,553, with 32,518,339 gross voting rights and 32,515,839 net voting rights. This aligns with December figures, indicating stability in share composition and voting rights. The report was issued under article 223-16 of the French AMF regulations, serving shareholders and investors with essential compliance data on voting power.

ERYTECH announced the presentation of clinical trial results for eryaspase in advanced pancreatic cancer at the ASCO GI symposium on January 21, 2022. The Phase 1 rESPECT trial showed a good safety profile and encouraging activity, with a 100% disease control rate in evaluable patients. The Phase 3 TRYbeCA-1 trial reported a non-significant overall survival increase but showed a potential benefit in a subgroup treated with FOLFIRI. The company is considering further studies and plans to submit a BLA for eryaspase in acute lymphoblastic leukemia.

Monthly Information on Voting Rights and Shares
This report provides details about the total number of voting rights and shares composing the share capital for Erytech Pharma as of December 31, 2021. The total number of shares has increased to 31,018,553, with total gross voting rights reaching 32,518,339. The net voting rights are noted as 32,515,839. This information complies with Article 223-16 of the French AMF General Regulation.